Most Read Articles
Jairia Dela Cruz, 03 May 2018
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Pearl Toh, 28 Aug 2017
Taking long-chain omega-3 fatty acids (LC-OM3) supplements, mainly EPA* and DHA** omega-3s, was associated with a modest but significant reduction in cardiac death risk, according to a meta-analysis of randomized controlled trials (RCTs).
Dr. Lau Hui Ling, 01 Aug 2017
Oral contraceptive selection should be individualized for each patient to yield maximum benefit.
18 Apr 2016
Copper intrauterine device exhibited superior efficacy to injectable progestin contraception in women attending termination of pregnancy services in South Africa, according to a pragmatic, open-label, parallel arm, randomised controlled trial.

Ultra-low-dose intravitreal bevacizumab improves severe, posterior ROP

06 Feb 2018

Using 0.16-mg intravitreal bevacizumab (IVB) has improved severe and posterior retinopathy of prematurity (ROP), with no adverse ocular outcomes occurring in the series, reports a recent study.

IVB injection was performed in 29 eyes of 15 infants. ‘Treatment success’ was defined as complete regression of retinopathy and vascularization into (or laser ablation of) zone 3.

Of the 29 eyes, 23 (79.3 percent) achieved primary success in response to IVB 0.16 mg alone, and 27 (93.1 percent) achieved secondary success, where additional treatment was required. During follow-up, one infant death was recorded due to respiratory disease.

Six of the total number of eyes (20.6 percent) underwent retreatment. Retreatments occurred at a mean of 9.8 weeks following initial IVB (range, 6‒15) and at a mean of 44 weeks postmenstrual age (range, 40‒50).

The authors conducted a retrospective observational case series of consecutive infants who underwent ultra-low-dose IVB injection for the management of ROP at a regional neonatal intensive care unit in the North East of England between November 2013 and August 2016.

IVB has emerged as an effective treatment modality for the management of severe and posterior ROP, but despite evidence of systemic vascular endothelial growth factor suppression and concerns about how this might affect the developing neonate, the optimal dose has remained unknown, according to the authors.

A 2013 study in Taiwan had shown the efficacy and safety of IVB injection in treating prethreshold ROP. Researchers, however, said that laser therapy might still be needed as backup treatment for patients who do not respond to an IVB injection or for those in whom ROP worsen after an IVB injection. [Am J Ophthalmol 2013;155:150-158.e1]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 03 May 2018
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Pearl Toh, 28 Aug 2017
Taking long-chain omega-3 fatty acids (LC-OM3) supplements, mainly EPA* and DHA** omega-3s, was associated with a modest but significant reduction in cardiac death risk, according to a meta-analysis of randomized controlled trials (RCTs).
Dr. Lau Hui Ling, 01 Aug 2017
Oral contraceptive selection should be individualized for each patient to yield maximum benefit.
18 Apr 2016
Copper intrauterine device exhibited superior efficacy to injectable progestin contraception in women attending termination of pregnancy services in South Africa, according to a pragmatic, open-label, parallel arm, randomised controlled trial.